Skip to Main Content

Author Details

Andrew L Hopkins
University of Dundee
1995
48
31
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
34168183Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.Sci Rep2021
34584208Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.Sci Rep2021
29908863Surveying GPCR solubilisation conditions using surface plasmon resonance.Anal Biochem2018
27994766Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening.ACS Med Chem Lett2016
25205347The Joint European Compound Library: boosting precompetitive research.Drug Discov Today2015
25857797Surface plasmon resonance analysis of seven-transmembrane receptors.Methods Enzymol2015
25992548Application of RNAi to Genomic Drug Target Validation in Schistosomes.PLoS Negl Trop Dis2015
24481311The role of ligand efficiency metrics in drug discovery.Nat Rev Drug Discov2014
25301577Fragment screening by SPR and advanced application to GPCRs.Prog Biophys Mol Biol2014
24944729Validity of ligand efficiency metrics.ACS Med Chem Lett2014
24454993Discovery of β2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor.ACS Med Chem Lett2013
22270643Quantifying the chemical beauty of drugs.Nat Chem2012
23235874Automated design of ligands to polypharmacological profiles.Nature2012
22860151Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases.PLoS Negl Trop Dis2012
21401504Rapid analysis of pharmacology for infectious diseases.Curr Top Med Chem2011
22004086Emerging role of surface plasmon resonance in fragment-based drug discovery.Future Med Chem2011
21765967Screening for GPCR Ligands Using Surface Plasmon Resonance.ACS Med Chem Lett2011
21878981Minimum information about a bioactive entity (MIABE).Nat Rev Drug Discov2011
21401510Progress in neglected disease drug discovery.Curr Top Med Chem2011
20047156The tetrahydrobiopterin pathway and pain.Curr Opin Investig Drugs2010
24900174Fragment screening by surface plasmon resonance.ACS Med Chem Lett2010
20559312Drug discovery: Know your chemical space.Nat Chem Biol2010
20375446An ontology for description of drug discovery investigations.J Integr Bioinform2010
19536101A crowdsourcing evaluation of the NIH chemical probes.Nat Chem Biol2009
19907483Drug discovery: Predicting promiscuity.Nature2009
18936753Network pharmacology: the next paradigm in drug discovery.Nat Chem Biol2008
18927591Genomic-scale prioritization of drug targets: the TDR Targets database.Nat Rev Drug Discov2008
17851512Mission possible.Nature2007
17921993Network pharmacology.Nat Biotechnol2007
16442279Can we rationally design promiscuous drugs?Curr Opin Struct Biol2006
17139284How many drug targets are there?Nat Rev Drug Discov2006
16841068Global mapping of pharmacological space.Nat Biotechnol2006
15109945Ligand efficiency: a useful metric for lead selection.Drug Discov Today2004
15537347Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.J Med Chem2004
15537346Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.J Med Chem2004
12647400Structural bioinformatics in drug discovery.Methods Biochem Anal2003
12664532Target analysis: a priori assessment of druggability.Ernst Schering Res Found Workshop2003
12546964Protein kinase drugs--optimism doesn't wait on facts.Drug Discov Today2002
12209152The druggable genome.Nat Rev Drug Discov2002
113842332-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.J Med Chem2001
10508433Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies.J Med Chem1999
10579814Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.J Med Chem1999
9772165Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.Biochemistry1998
9875411Allosteric inhibitors against HIV-1 reverse transcriptase: design and synthesis of MKC-442 analogues having an omega-functionalized acyclic structure.Antivir Chem Chemother1998
96891123'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.Proc Natl Acad Sci U S A1998
9108091Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.Proc Natl Acad Sci U S A1997
8648598Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.J Med Chem1996
8535785The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.Structure1995
  • 1 - 48 of 48

Recommended Authors

Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 2015
Number of shared co-authors 3
Department of Pharmaceutical Sciences, University of California San Francisco
Career Start Year 2009
Number of shared co-authors 4
University of Pittsburgh
Career Start Year 2006
Number of shared co-authors 0
Center for Molecular & Biomolecular Informatics, Radboud University Medical Center
Career Start Year 2006
Number of shared co-authors 0
Vertex Pharmaceuticals
Career Start Year 2004
Number of shared co-authors 8
St. Jude Children's Research Hospital
Career Start Year 2003
Number of shared co-authors 5
National Center for Advancing Translational Sciences, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 5
Inc. 16 Dekalb Pike
Career Start Year 2002
Number of shared co-authors 0
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 2002
Number of shared co-authors 7
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 1
Broad Institute
Career Start Year 1999
Number of shared co-authors 1
INSERM
Career Start Year 1998
Number of shared co-authors 0
Institute for Data Science and Computing, University of Miami
Career Start Year 1998
Number of shared co-authors 5
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 1997
Number of shared co-authors 0
Institut fur Pharmazeutische Chemie, Philipps-Universitat Marburg
Career Start Year 1996
Number of shared co-authors 2
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Career Start Year 1994
Number of shared co-authors 2
National Center for Advancing Translational Science, 9800 Medical Center Drive
Career Start Year 1993
Number of shared co-authors 2
Lilly Research Laboratories
Career Start Year 1990
Number of shared co-authors 1
Institute for Physiology, Charite-University Medicine Berlin
Career Start Year 1990
Number of shared co-authors 1
St. George's University Medical School
Career Start Year 1990
Number of shared co-authors 1
Blavatnik Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 0
Lilly Research Laboratories
Career Start Year 1989
Number of shared co-authors 1
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 1989
Number of shared co-authors 9
Leiden Academic Centre for Drug Research (LACDR), Leiden University
Career Start Year 1988
Number of shared co-authors 3
Boston University
Career Start Year 1987
Number of shared co-authors 0
European Bioinformatics Institute (EMBL-EBI)
Career Start Year 1987
Number of shared co-authors 9
Department of Pharmaceutical Sciences, University of Perugia
Career Start Year 1986
Number of shared co-authors 1
Lexicon Pharmaceuticals
Career Start Year 1983
Number of shared co-authors 2
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Career Start Year 1981
Number of shared co-authors 2
Lilly Research Laboratories
Career Start Year 1977
Number of shared co-authors 2

Collaborators

University of Oxford
Co-authored papers 13
Institute of Cardiovascular Science, University College London
Co-authored papers 5
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Pfizer Ltd
Co-authored papers 3
College of Life Sciences, University of Dundee
Co-authored papers 3
University of North Carolina School of Medicine
Co-authored papers 2
UNC Chapel Hill School of Medicine
Co-authored papers 2
Institut fur Biochemie und Molekularbiologie, Universitat Freiburg
Co-authored papers 2
University of Washington
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Institute of Cell and Molecular Biology, University of Edinburgh
Co-authored papers 1
Center for Emerging and Re-emerging Infectious Diseases, University of Washington
Co-authored papers 1
CSIR - National Chemical Laboratory
Co-authored papers 1
Peter MacCallum Cancer Centre
Co-authored papers 1
Co-authored papers 1
Connected Discovery Ltd
Co-authored papers 1
West Virginia University School of Medicine
Co-authored papers 1
University of New Mexico School of Medicine
Co-authored papers 1
European Bioinformatics Institute
Co-authored papers 1
Institute for Inorganic and Analytical Chemistry, Friedrich Schiller University Jena
Co-authored papers 1
Wellcome Sanger Institute
Co-authored papers 1
Co-authored papers 1
AGORA Cancer Research Center
Co-authored papers 1
EMBL's European Bioinformatics Institute (EMBL-EBI)
Co-authored papers 1
Bayer Healthcare Pharmaceuticals
Co-authored papers 1
Bio21 Molecular Science and Biotechnology Institute, University of Melbourne
Co-authored papers 1
University of Pennsylvania
Co-authored papers 1
Co-authored papers 1
Serono Research Institute
Co-authored papers 1